Appeal No. 94-3867
Application 07/808,075
54) or the carboxyl end terminal amino acid residue of the SP-C (claim 62).
A second aspect of the claimed invention is a method for treating hyaline membrane
disease or other syndromes associated with insufficient or abnormal surfactant material
which comprises administering an effective amount of the composition of either claim 54
or claim 62. See, e.g., claims 60 and 68.
Whitsett describes a purified composition of matter which comprises at least one
lipid and an SP-C. The SP-C of Whitsett is not covalently linked with a fatty acid. See,
e.g., the paragraph bridging pages 7-8 of Whitsett. The compositions of Whitsett are
useful for treating hyaline membrane disease (HMD). See, e.g., the last full paragraph of
page 9 of Whitsett.
Sokol describes a procedure for reacting a protein with an organic acid. The fatty
acids which maybe used in the procedure of Sokol include some of those required by the
claims on appeal. See, e.g., column 1, lines 46-68 of Sokol. The proteins used in the
procedure of Sokol are described at column 1, lines 37-45 as follows. The products
produced by Sokol are intended to be used “in cosmetics and other applications where
contact with the skin occurs” (column 1, lines 9-14).
The examiner believes that it would have been obvious to one of ordinary skill in the
art to modify the SP-C protein of Whitsett by covalently linking it with a fatty acid on
4
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: November 3, 2007